RxDoctor Payments Data

David Peters, MD

Internal Medicine · Kerrville, TXNPI 1275518912

Payments from drug & device makers

$507in general payments, 2019–2025

Across 23 payments — averaging $22.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$160
  • Acadia Pharmaceuticals Inc$98
  • AbbVie$86
  • GSK$71
  • AstraZeneca$47
  • Inspire Medical Systems, Inc.$24
  • plus $21 from 1 others

What the payments were for

  • Food & beverage$507100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$507 in reported general payments places this provider in the 60th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$294,198
Medicare patients
827
Services billed
4,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$168,127
TrulicityDulaglutide54$80,672
XareltoRivaroxaban64$73,146
JanuviaSitagliptin Phosphate67$70,080
AustedoDeutetrabenazine12$58,873
OzempicSemaglutide54$58,624
JardianceEmpagliflozin60$49,995
FarxigaDapagliflozin Propanediol35$48,411
CreonLipase/Protease/Amylase30$42,810
TradjentaLinagliptin36$40,609
MounjaroTirzepatide26$36,998
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$33,817
MyrbetriqMirabegron30$32,339
EntrestoSacubitril/Valsartan20$19,817
Breo ElliptaFluticasone/Vilanterol32$18,580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$21$117,67180 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$47$73,75083 claims
Novo NordiskOzempic$160$58,62454 claims
AbbVieCreon, Linzess, Synthroid$86$55,073158 claims
GSKTrelegy Ellipta, Breo Ellipta$71$52,39761 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Kerrville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →